184 related articles for article (PubMed ID: 28249055)
1. Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx?
Charokopos A; Muhammad T; Surbhi S; Brateanu A
J Fam Pract; 2017 Mar; 66(3):170-173. PubMed ID: 28249055
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
Page SR; Yee KC
Intern Med J; 2014 Jul; 44(7):690-3. PubMed ID: 25041770
[TBL] [Abstract][Full Text] [Related]
3. [Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case].
Deme D; Al-Hadad A; Varga T; Szántó E; Sándor K; Rakonczai E
Orv Hetil; 2009 Feb; 150(6):265-9. PubMed ID: 19179259
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
5. Insights Into Statin Intolerance.
Kopecky S; Baum S; Foody JM; Koren M; McKenney J; Sperling L; Wong ND;
Clin Cardiol; 2015 Sep; 38(9):520-6. PubMed ID: 26337173
[No Abstract] [Full Text] [Related]
6. Statin safety and drug interactions: clinical implications.
Bottorff MB
Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
[TBL] [Abstract][Full Text] [Related]
7. Statins and myotoxicity: a therapeutic limitation.
Tiwari A; Bansal V; Chugh A; Mookhtiar K
Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis and HMG-CoA reductase inhibitors.
Omar MA; Wilson JP; Cox TS
Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
[TBL] [Abstract][Full Text] [Related]
9. Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review.
Hsiao SH; Chang HJ; Hsieh TH; Kao SM; Yeh PY; Wu TJ
J Clin Pharm Ther; 2016 Oct; 41(5):575-8. PubMed ID: 27430348
[TBL] [Abstract][Full Text] [Related]
10. Case records of the Massachusetts General Hospital. Case 7-2012. A 79-year-old man with pain and weakness in the legs.
David WS; Chad DA; Kambadakone A; Hedley-Whyte ET
N Engl J Med; 2012 Mar; 366(10):944-54. PubMed ID: 22397657
[No Abstract] [Full Text] [Related]
11. Simvastatin-fluconazole causing rhabdomyolysis.
Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR
Ann Pharmacother; 2003; 37(7-8):1032-5. PubMed ID: 12841814
[TBL] [Abstract][Full Text] [Related]
12. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.
Magee CN; Medani SA; Leavey SF; Conlon PJ; Clarkson MR
Am J Kidney Dis; 2010 Nov; 56(5):e11-5. PubMed ID: 20888103
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions that interfere with statin metabolism.
Hirota T; Ieiri I
Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
[TBL] [Abstract][Full Text] [Related]
14. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
15. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
16. Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study.
Pedro-Botet J; Millán Núñez-Cortés J; Chillarón JJ; Flores-Le Roux JA; Rius J
Expert Opin Drug Saf; 2016 Dec; 15(12):1583-1587. PubMed ID: 27645494
[TBL] [Abstract][Full Text] [Related]
17. [Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
Bastida C; Also MA; Pericas JM; Letang E; Tuset M; Miró JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):579-82. PubMed ID: 24913991
[TBL] [Abstract][Full Text] [Related]
18. Statin myopathy: a common dilemma not reflected in clinical trials.
Fernandez G; Spatz ES; Jablecki C; Phillips PS
Cleve Clin J Med; 2011 Jun; 78(6):393-403. PubMed ID: 21632911
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
